Single Cell Proteomics for Personalized Medicine

Owing to the complexity of the intracellular metabolic pathways, an understanding of the intracellular pathways has been lagging behind the advances in gene expression. Multicolor FACS (fluorescence activated cell sorting) techniques combined with phosophospecific antibodies have been developed, enabling the determination of relative phosphorylation of signal transduction intermediates in individual cells. When stimulated with cytokines, individual leukemia cells exhibit marked differences in phosphoprotein patterns, which correspond with disease outcome. Thus, single cell phosphoproteomic techniques are superior to other proteomic

Table 18.2 Applications of pharmacoproteomic biomarkers in personalized medicine

Toxicoproteomics for prediction of toxicity during drug development

As markers of drug response and efficacy

For patient stratification in clinical trials

Protein biomarkers as common denominator of diagnostics and therapeutics

Tailoring of therapy in the postmarketing phase

© Jain PharmaBiotech

technologies for the molecular diagnosis of disease and development of personalized medicine. Although study of the phosphoprotein network is usually associated

with oncology, such a technology might be useful for other diseases for which multiple treatment options exist and competing technologies have not been able to adequately predict the optimal treatment for individual patients.

< Prev   CONTENTS   Source   Next >